BSX Boston Scientific Corp

  1. Stocks
  2. Healthcare
  3. NYSE: BSX

Price (delayed)

$42.33

Market cap

$60.6B

P/E Ratio

74.26

Dividend/share

N/A

EPS

$0.57

Enterprise value

$69.3B

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, ...

Highlights
The EPS has soared by 54% YoY and by 10% from the previous quarter
Boston Scientific's net income has surged by 52% YoY and by 9% QoQ
BSX's quick ratio is down by 48% year-on-year but it is up by 10% since the previous quarter
The P/E is 16% below the 5-year quarterly average of 88.9 but 11% above the last 4 quarters average of 67.1
Sector: Healthcare
Industry: Medical Devices
Website: https://www.bostonscientific.com/
Peers: EW SYK MMSI MDT

Key stats

What are the main financial stats of BSX
Market
Shares outstanding
1.43B
Market cap
$60.6B
Enterprise value
$69.3B
Valuations
Price to earnings (P/E)
74.26
Price to book (P/B)
3.51
Price to sales (P/S)
4.91
EV/EBIT
42.8
EV/EBITDA
25.3
EV/Sales
5.62
Earnings
Revenue
$12.33B
EBIT
$1.62B
EBITDA
$2.74B
Free cash flow
$684M
Per share
EPS
$0.57
Free cash flow per share
$0.48
Book value per share
$12.07
Revenue per share
$8.62
TBVPS
$9.06
Balance sheet
Total assets
$32.19B
Total liabilities
$14.94B
Debt
$8.97B
Equity
$17.25B
Working capital
$1.2B
Liquidity
Debt to equity
0.52
Current ratio
1.31
Quick ratio
0.56
Net debt/EBITDA
3.17
Margins
EBITDA margin
22.2%
Gross margin
68.9%
Net margin
7.2%
Operating margin
11.9%
Efficiency
Return on assets
2.6%
Return on equity
4.9%
Return on invested capital
9.4%
Return on capital employed
5.7%
Return on sales
13.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BSX stock price

How has the Boston Scientific stock price performed over time
Intraday
1.36%
1 week
3.4%
1 month
14.78%
1 year
-3.95%
YTD
-0.35%
QTD
13.58%

Financial performance

How have Boston Scientific's revenue and profit performed over time
Revenue
$12.33B
Gross profit
$8.49B
Operating income
$1.46B
Net income
$883M
Gross margin
68.9%
Net margin
7.2%
BSX's operating margin has surged by 183% year-on-year and by 11% since the previous quarter
Boston Scientific's net income has surged by 52% YoY and by 9% QoQ
Boston Scientific's net margin has increased by 38% YoY and by 7% QoQ
Boston Scientific's gross profit has increased by 13% YoY

Growth

What is Boston Scientific's growth rate over time

Valuation

What is Boston Scientific stock price valuation
P/E
74.26
P/B
3.51
P/S
4.91
EV/EBIT
42.8
EV/EBITDA
25.3
EV/Sales
5.62
The EPS has soared by 54% YoY and by 10% from the previous quarter
The P/E is 16% below the 5-year quarterly average of 88.9 but 11% above the last 4 quarters average of 67.1
The stock's price to book (P/B) is 22% less than its 5-year quarterly average of 4.5 and 2.5% less than its last 4 quarters average of 3.6
The equity has grown by 8% YoY and by 3.1% from the previous quarter
The revenue has increased by 10% YoY

Efficiency

How efficient is Boston Scientific business performance
BSX's ROIC has soared by 84% YoY and by 11% from the previous quarter
The ROS has soared by 62% YoY and by 10% from the previous quarter
The return on assets has surged by 53% year-on-year and by 8% since the previous quarter
The return on equity has increased by 44% year-on-year and by 7% since the previous quarter

Dividends

What is BSX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BSX.

Financial health

How did Boston Scientific financials performed over time
Boston Scientific's total assets is 115% more than its total liabilities
BSX's quick ratio is down by 48% year-on-year but it is up by 10% since the previous quarter
BSX's current ratio is down by 21% year-on-year but it is up by 11% since the previous quarter
Boston Scientific's debt is 48% lower than its equity
Boston Scientific's debt to equity has decreased by 9% YoY and by 7% from the previous quarter
The equity has grown by 8% YoY and by 3.1% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.